Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Doug Hanniford

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|November 11, 2018
Characterization of MicroRNAs Regulating FOXO ExpressionDoug Hanniford, Eva Hernando
Carcinogenesis|June 14, 2012
MicroRNA and cutaneous melanoma: from discovery to prognosis and therapyMiguel F Segura, Holly S Greenwald, Doug Hanniford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2015
A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain MetastasisDoug Hanniford, Judy Zhong, Lisa Koetz, et al.
Journal of the National Cancer Institute|February 14, 2015
Identification of metastasis-suppressive microRNAs in primary melanomaDoug Hanniford, Miguel F Segura, Judy Zhong, et al.
Cancer|August 27, 2014
Serum-based miRNAs in the prediction and detection of recurrence in melanoma patientsNathaniel H Fleming, Judy Zhong, Inês Pires da Silva, et al.
Cancer Research|August 17, 2013
BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapyMiguel F Segura, Bárbara Fontanals-Cirera, Avital Gaziel-Sovran, et al.
Journal of the National Cancer Institute|June 19, 2018
Primary Melanoma Histologic Subtype: Impact on Survival and Response to TherapyMichael Lattanzi, Yesung Lee, Danny Simpson, et al.
Bioorganic & Medicinal Chemistry Letters|May 12, 2010
3-Indolyl sultams as selective CRTh2 antagonistsL Nathan Tumey, Michael J Robarge, Elizabeth Gleason, et al.
Bioorganic & Medicinal Chemistry Letters|March 5, 2005
Isosteric ramatroban analogs: selective and potent CRTH-2 antagonistsMichael J Robarge, David C Bom, L Nathan Tumey, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Methods in Molecular Biology (Clifton, N.J.)|November 11, 2018
Characterization of MicroRNAs Regulating FOXO ExpressionDoug Hanniford, Eva Hernando
Carcinogenesis|June 14, 2012
MicroRNA and cutaneous melanoma: from discovery to prognosis and therapyMiguel F Segura, Holly S Greenwald, Doug Hanniford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2015
A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain MetastasisDoug Hanniford, Judy Zhong, Lisa Koetz, et al.
Journal of the National Cancer Institute|February 14, 2015
Identification of metastasis-suppressive microRNAs in primary melanomaDoug Hanniford, Miguel F Segura, Judy Zhong, et al.
Cancer|August 27, 2014
Serum-based miRNAs in the prediction and detection of recurrence in melanoma patientsNathaniel H Fleming, Judy Zhong, Inês Pires da Silva, et al.
Cancer Research|August 17, 2013
BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapyMiguel F Segura, Bárbara Fontanals-Cirera, Avital Gaziel-Sovran, et al.
Journal of the National Cancer Institute|June 19, 2018
Primary Melanoma Histologic Subtype: Impact on Survival and Response to TherapyMichael Lattanzi, Yesung Lee, Danny Simpson, et al.
Bioorganic & Medicinal Chemistry Letters|May 12, 2010
3-Indolyl sultams as selective CRTh2 antagonistsL Nathan Tumey, Michael J Robarge, Elizabeth Gleason, et al.
Bioorganic & Medicinal Chemistry Letters|March 5, 2005
Isosteric ramatroban analogs: selective and potent CRTH-2 antagonistsMichael J Robarge, David C Bom, L Nathan Tumey, et al.
Pageof 1